Roche: wins EU approval for breast cancer drug
(CercleFinance.com) - European health regulators have approved Roche's Kadcyla for the treatment of early-stage breast cancer, the Swiss drugmaker said on Thursday.
More specifically, the European Commission has approved Kadcyla for the treatment after surgery of adult patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment.
Kadcyla has been designed to deliver potent chemotherapy directly to cancer cells.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
More specifically, the European Commission has approved Kadcyla for the treatment after surgery of adult patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment.
Kadcyla has been designed to deliver potent chemotherapy directly to cancer cells.
Copyright (c) 2019 CercleFinance.com. All rights reserved.